Nausheen Ahmed
YOU?
Author Swipe
View article: Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals
Teclistamab Dosing Strategies in Relapsed/Refractory Myeloma: A Real-World Comparison of Weekly and Biweekly Versus Fixed Intervals Open
Background/Objectives: Teclistamab is a bispecific antibody targeting BCMA and CD3, approved for relapsed/refractory multiple myeloma. It is administered continuously until progression or intolerance; however, prolonged use may increase in…
View article: Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R Open
Introduction: Most patients diagnosed with primary mediastinal B-cell lymphoma (PMBCL) achieve cure following standard of care therapy with frontline DA-EPOCH-R. However, treatment strategies following relapse after DA-EPOCH-R are not well…
View article: CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World Setting Open
Improved understanding of the timing of cytokine release syndrome (CRS) and immune effector cell-mediated neurotoxicity syndrome (ICANS)/neurological events (NE) after chimeric antigen receptor (CAR) T-cell therapy infusion can inform pati…
View article: CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective
CAR-T Access Disparities for Multiple Myeloma in the Midwest: A Social Determinants of Health Perspective Open
Background: Multiple Myeloma (MM) is the most common type of blood cancer among black individuals. CAR-T therapy is crucial, but often inaccessible to many black patients and those from underserved communities. The University of Kansas Hea…
View article: Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review
Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic Review Open
CMV reactivation is a serious complication in CAR-T therapy, associated with higher mortality, relapse, and NRM. Key risk factors include BCMA-targeted CAR-T, prior allo-HSCT, and severe CRS/ICANS. Targeted monitoring and prophylactic stra…
View article: Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation
Concurrent intravenous immunoglobulin and platelet transfusion for refractory alloimmune thrombocytopenia in patients undergoing allogeneic hematopoietic stem cell transplantation Open
Continuous intravenous immunoglobulin and platelet infusions over 48 h may be able to overcome life-threatening refractory alloimmune thrombocytopenia in transplant patients and may provide a bridging measure until platelet engraftment or …
View article: Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience
Efficacy and Safety of Daratumumab, Pomalidomide and Dexamethasone Compared to Daratumumab, Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: Multicenter Real-World Experience Open
DPd and DKd demonstrated similar clinical efficacies in RRMM patients, although their toxicity profiles differed. These findings highlight the importance of individualized treatment decisions considering underlying patient comorbidities an…
View article: Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World Study
Outcomes of CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma by Race: A Multicenter Real-World Study Open
Racial and ethnic minorities have been underrepresented in pivotal trials of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), limiting the generalizability of findings. This multicenter retrospective study evalua…
View article: Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis
Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis Open
Brexucabtagene autoleucel (brexu-cel) is a chimeric antigen receptor T-cell therapy approved for relapsed/refractory mantle cell lymphoma (R/R MCL). Here, we report real-world effectiveness and safety outcomes of brexu-cel in a prospective…
View article: Effectiveness of Pelvic Floor Muscle Training in Preventing Urinary Incontinence After Vaginal Delivery: A Systematic Review
Effectiveness of Pelvic Floor Muscle Training in Preventing Urinary Incontinence After Vaginal Delivery: A Systematic Review Open
View article: Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study
Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study Open
View article: Global Access to Multiple Myeloma Therapies
Global Access to Multiple Myeloma Therapies Open
PURPOSE Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in …
View article: 458 | OPTIMIZING POST–CHIMERIC ANTIGEN RECEPTOR T CELL MONITORING: EVIDENCE ACROSS LISOCABTAGENE MARALEUCEL PIVOTAL CLINICAL TRIALS AND REAL‐WORLD EXPERIENCE
458 | OPTIMIZING POST–CHIMERIC ANTIGEN RECEPTOR T CELL MONITORING: EVIDENCE ACROSS LISOCABTAGENE MARALEUCEL PIVOTAL CLINICAL TRIALS AND REAL‐WORLD EXPERIENCE Open
View article: 455 | BENDAMUSTINE AS LYMPHODEPLETING CHEMOTHERAPY PRIOR TO AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
455 | BENDAMUSTINE AS LYMPHODEPLETING CHEMOTHERAPY PRIOR TO AXICABTAGENE CILOLEUCEL FOR THE TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA Open
View article: Analysis of COVID-19 Infection Dynamics: Extended SIR Model Approach
Analysis of COVID-19 Infection Dynamics: Extended SIR Model Approach Open
This paper presents a detailed mathematical investigation into the dynamics of COVID-19 infections through extended Susceptible-Infected-Recovered (SIR) and Susceptible-Exposed-Infected-Recovered (SEIR) epidemiological models. By incorpora…
View article: Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma
Standard-of-care idecabtagene vicleucel for relapsed/refractory multiple myeloma Open
Idecabtagene vicleucel (ide-cel) was the first US Food and Drug Administration–approved chimeric antigen receptor T-cell (CAR-T) therapy for multiple myeloma (MM). However, because clinical trials are highly selective with stringent eligib…
View article: A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma Open
View article: Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study
Outcomes of older adults and frail patients receiving idecabtagene vicleucel: a CIBMTR study Open
View article: Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis
Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis Open
Lisocabtagene maraleucel (liso-cel) is an autologous CD19-directed chimeric antigen receptor T-cell therapy approved for the treatment of relapsed/refractory large B-cell lymphoma. We present a multicenter retrospective study evaluating sa…
View article: Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy Open
Despite the astonishing outcomes after chimeric antigen receptor (CAR) T-cell therapy for relapsed refractory multiple myeloma (RRMM), most patients eventually relapse. There are only limited data available on salvage therapies following r…
View article: The current socioeconomic and regulatory landscape of immune effector cell therapies
The current socioeconomic and regulatory landscape of immune effector cell therapies Open
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent a transformative approach to cancer treatment, harnessin…
View article: A Real-World Experience of Efficacy and Safety of Belantamab Mafodotin in Relapsed Refractory Multiple Myeloma
A Real-World Experience of Efficacy and Safety of Belantamab Mafodotin in Relapsed Refractory Multiple Myeloma Open
While initial trials led to the accelerated approval of belantamab mafodotin, a BCMA directed antibody drug conjugate, confirmatory trials failed to establish benefit from this therapy for patients with relapsed refractory multiple myeloma…
View article: Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis
Siltuximab for chimeric antigen receptor T-cell therapy–related CRS and ICANS: a multicenter retrospective analysis Open
Chimeric antigen receptor T-cell (CAR-T) therapies are effective in many hematologic malignancies; however, adverse events including cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) can aff…
View article: BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma
BCMA-Directed MRD Detection as a Predictor of Relapse after BCMA CAR T in Multiple Myeloma Open
View article: Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review
Efficacy of Ruxolitinib with corticosteroids in idiopathic pneumonia syndrome post-allogeneic hematopoietic stem cell transplantation: A single-center experience and systematic review Open
The combination of Ruxolitinib and CS for treating IPS post-allo-HSCT suggested promising results in the case series, with favorable response and improved survival by blocking the cytokine production contributing to IPS. The significant mo…
View article: Safety and efficacy of <scp>B cell maturation antigen</scp>‐directed <scp>CAR T</scp>‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis
Safety and efficacy of <span>B cell maturation antigen</span>‐directed <span>CAR T</span>‐cell therapy in patients with relapsed/refractory multiple myeloma and concurrent light chain amyloidosis Open
Clinical trials evaluating chimeric antigen receptor (CAR) T‐cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the safety and efficacy o…
View article: Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma
Comparative Meta-Analysis of Triplet vs. Quadruplet Induction Regimens in Newly Diagnosed, Treatment Naïve, Multiple Myeloma Open
The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug combinations are lac…
View article: Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel
Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel Open
CD19–directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Ho…
View article: CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma
CD19-directed CART therapy for T-cell/histiocyte–rich large B-cell lymphoma Open
T-cell/histiocyte–rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19–directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. W…
View article: Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission
Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission Open
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We compared the efficac…